221 related articles for article (PubMed ID: 33220690)
1. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran.
Abdellahi L; Hejazi SH; Amirmozafari N; Sotoodehnejadnematalahi F
Arch Iran Med; 2020 Nov; 23(11):740-748. PubMed ID: 33220690
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
Sadeghian G; Nilforoushzadeh MA
Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory evaluation of cured and non-cured patients with cutaneous leishmaniasis treated by Glucantime.
Ezatkhah F; Sharifi I; Babaei Z; Baneshi MR; Zolala F; Kermanizadeh A; Keyhani A; Sharifi M; Dezaki ES; Aflatoonian MR; Aflatoonian B; Khatami M; Bamorovat M
J Vector Borne Dis; 2019; 56(4):351-359. PubMed ID: 33269736
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Nilforoushzadeh MA; Sadeghian G; Jaffary F; Ziaei H; Shirani-Bidabad L; Mahzoni P
Korean J Parasitol; 2008 Sep; 46(3):175-7. PubMed ID: 18830058
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological Trend of Cutaneous Leishmaniasis in an Endemic Focus Disease During 2009-2016, Central Iran.
Moein D; Masoud D; Mahmood N; Abbas D
Turkiye Parazitol Derg; 2019 Jun; 43(2):55-59. PubMed ID: 31204455
[TBL] [Abstract][Full Text] [Related]
7. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
Aflatoonian MR; Sharifi I; Aflatoonian B; Bamorovat M; Heshmatkhah A; Babaei Z; Ghasemi Nejad Almani P; Mohammadi MA; Salarkia E; Aghaei Afshar A; Sharifi H; Sharifi F; Khosravi A; Khatami M; Arefinia N; Fekri A; Farajzadeh S; Khamesipour A; Mohebali M; Gouya MM; Shirzadi MR; Varma RS
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007423. PubMed ID: 31188834
[TBL] [Abstract][Full Text] [Related]
8. A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models.
Bamorovat M; Sharifi I; Fekri A; Keyhani A; Aflatoonian MR; Heshmatkhah A; Oliaee RT; Khosravi A; Naderi A; Parizi MH; Mostafavi M; Varma RS
Microb Pathog; 2019 Mar; 128():162-170. PubMed ID: 30583021
[TBL] [Abstract][Full Text] [Related]
9. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.
Hadighi R; Mohebali M; Boucher P; Hajjaran H; Khamesipour A; Ouellette M
PLoS Med; 2006 May; 3(5):e162. PubMed ID: 16605301
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of 5% trichloroacetic acid cream in the treatment of cutaneous leishmaniasis lesions.
Ali NM; Fariba J; Elaheh H; Ali N
J Dermatolog Treat; 2012 Apr; 23(2):136-9. PubMed ID: 21034291
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
[TBL] [Abstract][Full Text] [Related]
13. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Moradi S; Derakhshan R; Haftbaradaran E
BMC Complement Altern Med; 2007 Apr; 7():13. PubMed ID: 17466071
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
Arboleda M; Barrantes S; Úsuga LY; Robledo SM
Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
[TBL] [Abstract][Full Text] [Related]
15. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
Rajabi O; Layegh P; Hashemzadeh S; Khoddami M
Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
[TBL] [Abstract][Full Text] [Related]
16. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
17. An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
Oliveira-Ribeiro C; Pimentel MIF; Oliveira LFA; Vasconcellos ÉCFE; Conceição-Silva F; Schubach AO; Fagundes A; de Mello CX; Mouta-Confort E; Miranda LFC; Valete-Rosalino CM; Martins ACDC; Oliveira RVC; Quintella LP; Lyra MR
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009734. PubMed ID: 34555016
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial.
Safi N; Davis GD; Nadir M; Hamid H; Robert LL; Case AJ
Mil Med; 2012 Mar; 177(3):345-51. PubMed ID: 22479925
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
Javadi A; Khamesipour A; Ghoorchi M; Bahrami M; Khatami A; Sharifi I; Eskandari SE; Fekri A; Aflatoonian MR; Firooz A
PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010569. PubMed ID: 35802749
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
Mohammadzadeh M; Behnaz F; Golshan Z
J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
